ArticleJournal of cancer survivorship : research and practice2019
Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Article in Journal of cancer survivorship : research and practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Pooled it
- Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.Journal of neurology · 2026Article
- Mind the Gaps: Literature Survey Reveals Shortcomings in Handling Missing Data in Clinical Practice Research Datalink (CPRD), a UK Primary Care Health Records Database.Clinical epidemiology · 2025Article
- Assessing Risk Factors for Cognitive Decline Using Electronic Health Record Data: A Scoping Review.Research square · 2024Article
- Alzheimer Disease and Related Dementia Following Hormone-Modulating Therapy in Patients With Breast Cancer.JAMA network open · 2024Article
- Risk of All-Cause Dementia, Alzheimer Disease, and Vascular Dementia in Breast Cancer Survivors: A Longitudinal Register-Based Study.Neurology. Clinical practice · 2023Article
- A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors.Cancers · 2023Review
- Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.Frontiers in aging neuroscience · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeAmong a cohort of postmenopausal breast cancer survivors, we aimed to compare the risk of dementia associated with aromatase inhibitor (AI) therapy versus tamoxifen.
methodsUsing UK primary care electronic health records, we identified 14,214 postmenopausal breast cancer survivors (aged ≥ 54 years) with a first AI or tamoxifen prescription between January 2002 and December 2015 and no previous dementia diagnosis. Women were followed-up to identify incident cases of dementia. Cox regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) to quantify the association between AI exposure (vs. tamoxifen) and dementia, adjusted for confounders.
resultsA total of 368 incident dementia cases was identified over 57,102 person-years of follow-up. The crude incidence rate of dementia was 7.46 per 1000 person-years (95% CI 6.43-8.65) among women starting endocrine treatment on an AI, and 6.32 per 1000 person-years (95% CI 5.34-7.47) among women starting on tamoxifen. After accounting for age differences and assessing other potential confounders, there was no evidence of a difference in dementia risk between exposure groups (HR for AI vs tamoxifen 1.04, 95% CI 0.83-1.03). There was no evidence of effect modification by age.
conclusionThere was no evidence for a difference in dementia risk between AI and tamoxifen users among postmenopausal breast cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: Our findings suggest that there is no reason for concern about a difference in dementia risk with AI vs. tamoxifen, which is relevant to postmenopausal breast cancer patients recommended these treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.